Snowden Capital Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Snowden Capital Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Sell	3,782 -441	-10%	-$24.5K	0.01%	1229
2026 Q1	$246K	Buy	+4,223	New	+$195K	0.01%	1111
2024 Q3	–	Sell	-5,511	Closed	-$215K	–	1262
2024 Q2	$215K	Buy	5,511 +12	+0.2%	+$480	0.01%	1116
2024 Q1	$237K	Sell	5,499 -224	-4%	-$10.3K	0.01%	1067
2023 Q4	$264K	Sell	5,723 -142	-2%	-$5.02K	0.01%	962
2023 Q3	$200K	Sell	5,865 -131	-2%	-$4.9K	0.01%	1022
2023 Q2	$231K	Buy	+5,996	New	+$238K	0.01%	1051

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Snowden Capital Advisors's XENE Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 10% in Q2 2026, selling an estimated $24.5K and leaving 3,782 shares worth $228K. The position accounts for 0.01% of the portfolio, ranked #1229.

Snowden Capital Advisors first reported a position in XENE in Q2 2023 and has held it in 7 quarters since. The position peaked at $264K in Q4 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Snowden Capital Advisors held 3,782 shares of Xenon Pharmaceuticals worth $228K as of Q2 2026.
Snowden Capital Advisors sold 441 Xenon Pharmaceuticals shares in Q2 2026, an estimated $24.5K.
Xenon Pharmaceuticals made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1229 holding.
Snowden Capital Advisors first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Snowden Capital Advisors's Xenon Pharmaceuticals position peaked at $264K in Q4 2023.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.